Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review

Global Markets Direct’s, ‘Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Sumitomo Dainippon Pharma Co Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sumitomo Dainippon Pharma Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Sumitomo Dainippon Pharma Co Ltd

The report provides overview of Sumitomo Dainippon Pharma Co Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Sumitomo Dainippon Pharma Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Sumitomo Dainippon Pharma Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Sumitomo Dainippon Pharma Co Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sumitomo Dainippon Pharma Co Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sumitomo Dainippon Pharma Co Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Sumitomo Dainippon Pharma Co Ltd Snapshot 8

Sumitomo Dainippon Pharma ...

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Sumitomo Dainippon Pharma Co Ltd Snapshot 8

Sumitomo Dainippon Pharma Co Ltd Overview 8

Key Facts 8

Sumitomo Dainippon Pharma Co Ltd - Research and Development Overview 9

Key Therapeutic Areas 9

Sumitomo Dainippon Pharma Co Ltd - Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products - Monotherapy 14

Pipeline Products - Partnered Products 15

Partnered Products/Combination Treatment Modalities 16

Pipeline Products - Out-Licensed Products 17

Out-Licensed Products/Combination Treatment Modalities 18

Sumitomo Dainippon Pharma Co Ltd - Pipeline Products Glance 19

Sumitomo Dainippon Pharma Co Ltd - Late Stage Pipeline Products 19

Pre-Registration Products/Combination Treatment Modalities 19

Phase III Products/Combination Treatment Modalities 20

Sumitomo Dainippon Pharma Co Ltd - Clinical Stage Pipeline Products 21

Phase II Products/Combination Treatment Modalities 21

Phase I Products/Combination Treatment Modalities 22

Sumitomo Dainippon Pharma Co Ltd - Early Stage Pipeline Products 23

Preclinical Products/Combination Treatment Modalities 23

Discovery Products/Combination Treatment Modalities 25

Sumitomo Dainippon Pharma Co Ltd - Drug Profiles 26

amrubicin hydrochloride - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

blonanserin - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

DSP-0011 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

DSP-1200 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

DSP-6952 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

DSP-7888 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

DSR-17759 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

DSR-6434 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

DSR-71167 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DSR-98776 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

EPI-589 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

HLS-001 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

lurasidone hydrochloride - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

NEP-28 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

obeticholic acid - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

SM-276001 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

SM-295291 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

SM-369926 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Small Molecule for Epilepsy - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Small Molecule for Pruritus - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Small Molecules to Inhibit CaMKII for Undisclosed Indication - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecules to Inhibit mPGES-1 for Inflammation - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecules to Target Ras Signaling Pathway for Cancer - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

SMP-304 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

vatiquinone - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

WT-2725 - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

WT-4869 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

zonisamide - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Sumitomo Dainippon Pharma Co Ltd - Pipeline Analysis 84

Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Target 84

Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Route of Administration 86

Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Molecule Type 87

Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Mechanism of Action 88

Sumitomo Dainippon Pharma Co Ltd - Dormant Projects 91

Sumitomo Dainippon Pharma Co Ltd - Discontinued Pipeline Products 93

Discontinued Pipeline Product Profiles 94

ceftaroline fosamil 94

DSP-0565 94

DSP-3025 94

DSP-7238 94

DSP-9599 94

emapunil 94

indiplon 95

KGA-3235 95

limaprost 95

rafabegron 95

ranirestat 95

razupenem 95

resequinil 95

rimacalib 95

SEP-225425 95

SEP-226332 96

SEP-227162 96

SEP-227900 96

SMP-028 96

SMP-797 96

Sumitomo Dainippon Pharma Co Ltd - Company Statement 97

Sumitomo Dainippon Pharma Co Ltd - Locations And Subsidiaries 98

Head Office 98

Other Locations & Subsidiaries 98

Appendix 102

Methodology 102

Coverage 102

Secondary Research 102

Primary Research 102

Expert Panel Validation 102

Contact Us 102

Disclaimer 103

List of Tables

List of Tables

Sumitomo Dainippon Pharma Co Ltd, Key Facts 8

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Indication, 2016 10

Sumitomo Dainippon Pharma ...

List of Tables

Sumitomo Dainippon Pharma Co Ltd, Key Facts 8

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Indication, 2016 10

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Stage of Development, 2016 13

Sumitomo Dainippon Pharma Co Ltd - Monotherapy Products in Pipeline, 2016 14

Sumitomo Dainippon Pharma Co Ltd - Partnered Products in Pipeline, 2016 15

Sumitomo Dainippon Pharma Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 16

Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products in Pipeline, 2016 17

Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 18

Sumitomo Dainippon Pharma Co Ltd - Pre-Registration, 2016 19

Sumitomo Dainippon Pharma Co Ltd - Phase III, 2016 20

Sumitomo Dainippon Pharma Co Ltd - Phase II, 2016 21

Sumitomo Dainippon Pharma Co Ltd - Phase I, 2016 22

Sumitomo Dainippon Pharma Co Ltd - Preclinical, 2016 23

Sumitomo Dainippon Pharma Co Ltd - Discovery, 2016 25

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Target, 2016 84

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Route of Administration, 2016 86

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Molecule Type, 2016 87

Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Mechanism of Action, 2016 89

Sumitomo Dainippon Pharma Co Ltd - Dormant Developmental Projects,2016 91

Sumitomo Dainippon Pharma Co Ltd - Discontinued Pipeline Products, 2016 93

Sumitomo Dainippon Pharma Co Ltd, Other Locations 98

Sumitomo Dainippon Pharma Co Ltd, Subsidiaries 101

List of Figures

List of Figures

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Indication, 2016 10

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Stage ...

List of Figures

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Indication, 2016 10

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Stage of Development, 2016 13

Sumitomo Dainippon Pharma Co Ltd - Monotherapy Products in Pipeline, 2016 14

Sumitomo Dainippon Pharma Co Ltd - Partnered Products in Pipeline, 2016 15

Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products in Pipeline, 2016 17

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Target, 2016 84

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Route of Administration, 2016 86

Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Molecule Type, 2016 87

Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016 88

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports